SCHEMBL30340726

SCHEMBL30340726

c1ccc2c(c1)CNc1ccccc1-c1nn[nH]c1-2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.40
▸ CA9 Q16790 2/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ JAK2 O60674 1/20 0.38
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ PLK4 O00444 1/20 0.36
▸ DAPK3 O43293 1/20 0.36
▸ PIM1 P11309 1/20 0.36
▸ PDGFRA P16234 1/20 0.36
▸ LTK P29376 1/20 0.36
▸ MAP2K2 P36507 1/20 0.36
▸ FLT3 P36888 1/20 0.36
▸ MAPK8 P45983 1/20 0.36
▸ MAPK9 P45984 1/20 0.36
▸ CSNK1A1 P48729 1/20 0.36
▸ TDO2 P48775 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17949690 1.00 CA12 (0.40) CA12CA9ALOX15HSD17B10JAK2
SCHEMBL20503690 0.94 CA12 (0.40) CA12CA9ALOX15HSD17B10JAK2
SCHEMBL30096606 0.94 CA12 (0.40) CA12CA9ALOX15HSD17B10JAK2
SCHEMBL23044043 0.78 KDM4E (0.41) PLK4DAPK3PIM1PDGFRALTK
SCHEMBL21340386 0.76 ACVR1 (0.39) GAAPDGFRALTKCDK8CDK5
SCHEMBL20854469 0.75 METAP2 (0.53) CA12CA9ALOX15HSD17B10JAK2
Dihydrophenanthridine SCHEMBL29791568 0.73 CA12 (0.56) CA12CA9ALOX15HSD17B10JAK2
Dihydrophenanthridine SCHEMBL2087461 0.73 CA12 (0.56) CA12CA9ALOX15HSD17B10JAK2
SCHEMBL24976109 0.73 ALDH1A1 (0.37) HSD17B10GAAPLK4DAPK3PIM1
SCHEMBL727511 0.73 ALDH1A1 (0.37) HSD17B10GAAPLK4DAPK3PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630047-A1 VACCINE AGAINST KLEBSIELLA PNEUMONIAE Idorsia Pharmaceuticals Ltd (CH) 2025-10-15 — — EP disclosed
EP-4608439-A1 VACCINE AGAINST KLEBSIELLA PNEUMONIAE Idorsia Pharmaceuticals Ltd (CH) 2025-09-03 — — EP disclosed
WO-2024121280-A1 VACCINE AGAINST KLEBSIELLA PNEUMONIAE IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-13 — — WO disclosed
WO-2024089001-A1 VACCINE AGAINST KLEBSIELLA PNEUMONIAE IDORSIA PHARMACEUTICALS LTD (CH) 2024-05-02 — — WO disclosed
US-20230108299-A1 GLYCOTARGETING THERAPEUTICS ANOKION SA (CH) 2023-04-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230108299-A1 GLYCOTARGETING THERAPEUTICS B3GAT3, UGGT1, MRGPRX1 CA12 1955/4885CA9 1702/4885ALOX15 561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback